Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

Trial Profile

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Facial-wrinkles
  • Focus Registrational; Therapeutic Use
  • Acronyms REALISE1
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 08 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 13 Jun 2016 According to a Revance Therapeutics media release, based on the disappointing results of this trial, the company has decided to disontinue the development of RT001 topical for crow's feet. Based on these results, they company has also decided not to pursue the current clinical development plan for RT001 in axillary hyperhidrosis.
    • 13 Jun 2016 Primary endpoint (The primary efficacy endpoints are composites based upon the Investigators Global Assessment of Lateral Canthal Lines (IGA-LCL) assessment and the Patient Severity Assessment (PSA) between baseline and 28 days after treatment.) has not been met, according to a Revance Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top